Mechanism of Qiwei Baizhu San in the Treatment of T2DM by Regulating Liver miRNA

Objective: To investigate the mechanism of Qiwei Baizhu San in the treatment of T2DM by regulating liver miRNA. Methods: Establish the T2DM rat model by STZ injection combined with high sugar and high-fat diet induction. On the basis of previous research, three rats were randomly selected from model group, control group and treatment group respectively. Transcriptome sequencing was performed on the liver to screen its miRNA differential genes. Target genes were predicted through five databases such as miRDB, and miRNA-mRNA relationship pairs were constructed; After mRNA intersection of model group vs. control group and treatment group vs. model group, target genes were obtained, and PPI, GO and KEGG analyses were performed; The mRNA of Qiwei Baizhu San collected through TCMSP database and the target genes obtained by sequencing were again intersected. The active components corresponding to the target genes were obtained by reverse network pharmacology. The target points corresponding to the core components were screened according to the Degree value and verified by molecular docking. Results: There were 14 differential miRNAs that met the screening conditions in model group vs. control group; In treatment group vs. model group, miRNA differential genes were miR-204-5p and miR-224-5p. After the miRNA intersection in model group vs. control group and treatment group vs. model group, it was found that it regulated 194 mRNA. PPI analysis showed that the key genes were MAPK8, TFRC, SORT1, NTRK2, HNRNPC and AP1S2. The GO analysis results showed that the function was mainly enriched in BP mesenchymal cell development, and KEGG was mainly enriched in Pathways in cancer and PI3K-Akt signaling pathway. The active components obtained by reverse network pharmacology were lappadilactone, Cerevisterol and Genkwanin. The molecular docking results showed that the key active components had good binding with the core target. Conclusion: By regulating miR-204-5p and miR-2245p, Qiwei Baizhu San could target MAPK8, TFRC, SORT1 and other genes. Through mesenchymal cell development, PI3K-Akt signaling pathway and other pathways, it could affect glucose and lipid metabolism, improve IR, and play a role in treating T2DM
¹
.